MXPA96004448A - Use of carboxylic acid derivatives comomedicamen - Google Patents
Use of carboxylic acid derivatives comomedicamenInfo
- Publication number
- MXPA96004448A MXPA96004448A MXPA/A/1996/004448A MX9604448A MXPA96004448A MX PA96004448 A MXPA96004448 A MX PA96004448A MX 9604448 A MX9604448 A MX 9604448A MX PA96004448 A MXPA96004448 A MX PA96004448A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- phenyl
- alkoxy
- alkylthio
- radicals
- Prior art date
Links
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title claims abstract description 14
- -1 cyano, hydroxy Chemical group 0.000 claims abstract description 153
- 125000005843 halogen group Chemical group 0.000 claims abstract description 60
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 54
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 40
- 150000002367 halogens Chemical class 0.000 claims abstract description 32
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 25
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 20
- 239000001301 oxygen Substances 0.000 claims abstract description 20
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims abstract description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 239000001257 hydrogen Substances 0.000 claims abstract description 14
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims abstract description 14
- 239000011593 sulfur Substances 0.000 claims abstract description 13
- 125000004434 sulfur atoms Chemical group 0.000 claims abstract description 12
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000004430 oxygen atoms Chemical group O* 0.000 claims abstract description 8
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract description 5
- 125000004432 carbon atoms Chemical group C* 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims abstract description 3
- 125000004429 atoms Chemical group 0.000 claims abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 12
- 125000006678 phenoxycarbonyl group Chemical group 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drugs Drugs 0.000 claims description 5
- 150000002431 hydrogen Chemical group 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract description 9
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract description 3
- 101710008828 UQCRB Proteins 0.000 abstract description 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 abstract description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 description 44
- 150000001875 compounds Chemical class 0.000 description 33
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 23
- 239000002904 solvent Substances 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- 102000002045 Endothelin Human genes 0.000 description 16
- 108050009340 Endothelin Proteins 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cells Anatomy 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 150000004702 methyl esters Chemical class 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 102100004921 EDN1 Human genes 0.000 description 7
- 108010072834 Endothelin-1 Proteins 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 102000010180 Endothelin Receptors Human genes 0.000 description 4
- 108050001739 Endothelin Receptors Proteins 0.000 description 4
- 230000003042 antagnostic Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 206010020852 Hypertonia Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002308 endothelin receptor antagonist Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000005842 heteroatoms Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 150000002829 nitrogen Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- 125000006050 3-methyl-2-pentenyl group Chemical group 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 208000006673 Asthma Diseases 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N Boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000007322 Death, Sudden, Cardiac Diseases 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N Lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 208000002815 Pulmonary Hypertension Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010038435 Renal failure Diseases 0.000 description 2
- 206010049418 Sudden cardiac death Diseases 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002490 cerebral Effects 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- NPUZFKMKEFBWLV-SNAWJCMRSA-N (E)-pent-2-ene Chemical group [CH2]C\C=C\C NPUZFKMKEFBWLV-SNAWJCMRSA-N 0.000 description 1
- 125000006079 1,1,2-trimethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006059 1,1-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000004747 1,1-dimethylethoxycarbonyl group Chemical group CC(C)(OC(=O)*)C 0.000 description 1
- 125000004866 1,1-dimethylethylcarbonyl group Chemical group CC(C)(C(=O)*)C 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000006062 1,2-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006035 1,2-dimethyl-2-propenyl group Chemical group 0.000 description 1
- 125000006063 1,2-dimethyl-3-butenyl group Chemical group 0.000 description 1
- 125000006065 1,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006066 1,3-dimethyl-3-butenyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000004678 1-methylpropylcarbonyl group Chemical group CC(CC)C(=O)* 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004781 2,2-dichloro-2-fluoroethyl group Chemical group [H]C([H])(*)C(F)(Cl)Cl 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- 125000006067 2,2-dimethyl-3-butenyl group Chemical group 0.000 description 1
- 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- WKFQMDFSDQFAIC-UHFFFAOYSA-N 2,4-dimethylthiolane 1,1-dioxide Chemical compound CC1CC(C)S(=O)(=O)C1 WKFQMDFSDQFAIC-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000004780 2-chloro-2,2-difluoroethyl group Chemical group [H]C([H])(*)C(F)(F)Cl 0.000 description 1
- 125000006077 2-ethyl-2-butenyl group Chemical group 0.000 description 1
- 125000006078 2-ethyl-3-butenyl group Chemical group 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006049 2-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006056 2-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004746 2-methylpropyloxycarbonyl group Chemical group CC(COC(=O)*)C 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006054 3-methyl-3-pentenyl group Chemical group 0.000 description 1
- AOTYHQRORSTIDY-UHFFFAOYSA-N 3-methyl-3-phenyloxirane-2-carboxylic acid Chemical compound C=1C=CC=CC=1C1(C)OC1C(O)=O AOTYHQRORSTIDY-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- PCVRHOZHSQQRMC-UHFFFAOYSA-N 4,6-dimethoxy-1H-pyrimidine-2-thione Chemical compound COC1=CC(OC)=NC(S)=N1 PCVRHOZHSQQRMC-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- IUNSZYPFRNLDFV-UHFFFAOYSA-N 4-ethoxy-2-methylsulfonylpyrimidine Chemical compound CCOC1=CC=NC(S(C)(=O)=O)=N1 IUNSZYPFRNLDFV-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000006051 4-methyl-2-pentenyl group Chemical group 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N Amyl acetate Chemical compound CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 210000000709 Aorta Anatomy 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229960003071 Bacitracin Drugs 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- SEPZQYRGBSYKQS-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(C(C(=O)O)O)(C)C1=CC=CC=C1 Chemical compound C(C1=CC=CC=C1)OC(C(C(=O)O)O)(C)C1=CC=CC=C1 SEPZQYRGBSYKQS-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 210000001715 Carotid Arteries Anatomy 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 210000001638 Cerebellum Anatomy 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 210000004351 Coronary Vessels Anatomy 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 210000003989 Endothelium, Vascular Anatomy 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229910001242 Iron–hydrogen alloy Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N Isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N Methyl isopropyl ketone Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N Propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud Disease Diseases 0.000 description 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 description 1
- 206010038436 Renal failure acute Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 206010042316 Subarachnoid haemorrhage Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium(0) Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 201000006474 brain ischemia Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 239000007809 chemical reaction catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 125000004789 chlorodifluoromethoxy group Chemical group ClC(O*)(F)F 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910000049 iron hydride Inorganic materials 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- MPUUYNKMYOCSAO-UHFFFAOYSA-N methyl 2-(4,6-dimethoxypyrimidin-2-yl)oxy-3-phenoxy-3-phenylbutanoate Chemical compound C=1C=CC=CC=1OC(C)(C=1C=CC=CC=1)C(C(=O)OC)OC1=NC(OC)=CC(OC)=N1 MPUUYNKMYOCSAO-UHFFFAOYSA-N 0.000 description 1
- XXRIHIOVKDEJPJ-UHFFFAOYSA-N methyl 2-hydroxy-3-phenoxy-3-phenylbutanoate Chemical compound C=1C=CC=CC=1C(C)(C(O)C(=O)OC)OC1=CC=CC=C1 XXRIHIOVKDEJPJ-UHFFFAOYSA-N 0.000 description 1
- DYDIMXGJVTUIIK-UHFFFAOYSA-N methyl 2-hydroxy-3-phenyl-3-phenylmethoxybutanoate Chemical compound C=1C=CC=CC=1C(C)(C(O)C(=O)OC)OCC1=CC=CC=C1 DYDIMXGJVTUIIK-UHFFFAOYSA-N 0.000 description 1
- AGZSSAGYWIIPFE-UHFFFAOYSA-N methyl 3-methyl-3-phenyloxirane-2-carboxylate Chemical compound COC(=O)C1OC1(C)C1=CC=CC=C1 AGZSSAGYWIIPFE-UHFFFAOYSA-N 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- OCFVSFVLVRNXFJ-UHFFFAOYSA-N potassium hydride Inorganic materials [H-].[K+] OCFVSFVLVRNXFJ-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-O pyrazolium Chemical compound C1=CN[NH+]=C1 WTKZEGDFNFYCGP-UHFFFAOYSA-O 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000035812 respiration Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- POECFFCNUXZPJT-UHFFFAOYSA-M sodium;carbonic acid;hydrogen carbonate Chemical compound [Na+].OC(O)=O.OC([O-])=O POECFFCNUXZPJT-UHFFFAOYSA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- LCKIEQZJEYYRIY-UHFFFAOYSA-N titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- BZVJOYBTLHNRDW-UHFFFAOYSA-N triphenylmethanamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(N)C1=CC=CC=C1 BZVJOYBTLHNRDW-UHFFFAOYSA-N 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Abstract
The present invention relates to the use of carboxylic acid derivatives of the general formula I: wherein R means a formyl group, a group CO2H, R2 halogen, C1-C4 alkyl and others, X nitrogen or CR14 and others, R3 halogen, C1-C4-alkyl and others, R4 a C1-C10-alkyl group and others, a C1-C10-alkyl group, which carries one to five halo atoms and other radicals, a C3-C12-cycloalkyl or C3-C12-cycloalkenyl group , which may contain an oxygen or sulfur atom and carry one to five halo atoms and other radicals, a C3-C6-alkenyl or C3-C6-alkynyl group, which may each carry one to five halo atoms and / or one of the following radicals: C1-C4-alkyl, C1-C4-alkoxy and others, a heteroaromatic of five or six members, containing one to three nitrogen atoms and / or one sulfur or oxygen atom, which can carry one to four halogen atoms and / or one to two of the following radicals: C1-C4-alkyl and others, phenyl or naft ilo, which may be substituted by one or more radicals: halogen, nitro, cyano, hydroxy, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, C1-C4- alkylthio, amino, C1-C4-alkylamino or C1-C4-dialkylamino; R4 and R5 form together with the neighboring carbon atom a ring of 3 to 8 members, which may contain an oxygen or sulfur atom and carry one to three radicals; C1-C4-alkyl and others, R5 hydrogen, C1-C4-alkyl and others, R6 C1-C8-alkyl, C3-C6-alkenyl, C3-C6-alkynyl or C3-C8-cycloalkyl, whose radicals may be mono or polysubstituted, phenyl or naphthyl, which may be substituted each time by one or several radicals: halogen and others, a heteroaromatic of five or six members, containing one to three nitrogen atoms and / or one atom of sulfur or oxygen, which may carry one up to four halo atoms and / or one to two of the following radicals: C1-C4 alkyl and otr
Description
Use of carboxylic acid derivatives as medicines
Description
The present invention relates to the use of certain carboxylic acid derivatives as medicaments.
Endothelin is a peptide composed of 21 amino acids, which is synthesized and released by the vascular endothelium. Endote-lina exists in three isomeric forms. ET-1, ET-2 and ET-3. Hereinafter, the term "in otelin" or "ET" will encompass one or more isomeric forms of endothelin. Endothelin is a potent vasoconstrictor and has a strong effect on vascular tone. AND? It is known that this vascular constriction is produced by the binding of endothelin with its receptor (Nature, 332, 411-415, 1988; FEBS Letters, 2 1, 440-444, 1988 and Biochem. Biophys., Res. Comroun., 1 £ 4, 868-875, 1988).
An increased or abnormal libration of endothelin will cause prolonged contraction of the peripheral, renal and cerebral vessels, a phenomenon that can result in diseases. According to the literature, high levels of endothelin are found in the plasma in patients suffering from hypertonia, acute myocardial infacet, pulmonary hypertension, Raynaud's syndrome, acerosclerosis, and in the respiratory tract of asthmatics. { Japan J, Hypertension, 12., 79 (1989), J. Vascular Med. Biology 2, 207 (1990), J. Am. Med. Association 264, 2868 (1990)).
Thus, substances that specifically inhibit endothelial ligation with the receptor must antagonize the different physiological effects of endothelin, which is why they are valuable drugs.
It has now been found that certain carboxylic acid derivatives are good inhibitors for endothelin receptors.
The object of the present invention is the use of carboxylic acid derivatives, which correspond to formula I below, for the production of drugs, especially for obtaining inhibitors for endothelin receptors.
Carboxylic acid derivatives of the general formula i
wherein R means a formyl group, a co-H group or a hydrolysable radical in COOH and the other substituents have the following meanings:
R "halogen, Cj-C.i-alkyl, d-C, -halogenoalkyl, C? -C4-alkoxy, Ci-Cj-halogenoalkoxy or d-C ^ -alkylthio;
X nitrogen 'or CR14, where 1 * means hydrogen or form together with R: an alkylene or alkenyl chain with 3 to 4 members, in which a methylene group respectively is substituted by oxygen;
R3 halogen, Ci-Ca-haloalkyl, C1-C4-alkoxy, C? -C "-haloalcoal? I, C? -C: -alkylthio or R3 is attached with R14, as indicated above, forming a ring of 5 6 6 members;
R *? N group C? -Cln-aikyl, which can carry one to five halogen atoms / or one of the following radicals: C? -C ~ alkoxy, C] .- C -? - alkylthio, cyano, Ci-? Ct-alkylcarbonyl, C] .- Ca-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, the phenyl radicals being capable of carrying one to five halogen atoms and / or one to three of the following radicals: Ci-C -alkyl, Ci-d.-halogenoalkyl, Cj-Ci-alkoxy, C: -C4 -haiogenoalkoxy and / or C? -C4-alkylthio;
l-? fftupo Ci-Cic-alkyl, which carries one to five halogen atoms and one of the following radicals: a five-membered heteroaromatic containing one to three nitrogen atoms and / or a sulfur or oxygen atom, which can carry one to four halogen atoms and / or one to do3 of the following radicals: c -.- C, -alkyl, Ci-Cd-halogencalkyl, Ci-Cj-alkoxy, C? -C4-halogenoalkoxy, C? -C4- alkylthio and / or phenyl;
a group which may contain an oxygen or sulfur atom and carry one to five halogen atoms and / or one of the following radicals: Ci-Cj-alkyl, C1-C4-alkoxy, C? -C4-alkylthio, cyano, Ci -C, -alkylcarbonyl, C? -C6-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, whose phenyl radicals can in turn carry one to five halogen atoms and / or one to three of the following radicals: 5 C- -Cj-alkyl, C: ~ Cis-halogen, C: .- C4-alkoyl, C: -C'4-halogenoalkyl, and / or C-, -C_-alkylthio;
a C3-C-alkenyl group or C:, - C.- ~ alkynyl, which can each carry one to five halogen atoms and / or one of the following 10 radicals: C.-C -.- alkyl, CC, -alkoxy, C? -C4-alkylthio, cyano, Ci-C? -alkylcarbonyl, C? Cg-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, whose phenyl radicals can in turn carry one to five halogen atoms and / or one to three of the following
radicals: C-Cí-alkyl, C: -C -halogenalkyl, d-C4-alkoxy, Ci-Ci-haloalkoxy and C-Cz-alkylthio;
a heteroaromatic of five or six members, containing one to three nitrogen atoms and / or one sulfur atom
or oxygen, which can carry one to four halogen atoms and / or one to two of the following radicals: C-C4-alkyl, Ci-d-haloalkyl, C- | -C < -alkoxy, c1-c4-halogenoalkoxy, C ^ -C ^ -alquiltis, phenyl, phenoxy or phenylcarbonyl, whose phenyl radicals can carry
parts one to five halogen atoms and / or one to three of the following radicals: C: ~ C ~ alkyl, Ci-Cí-haloalkyl, C 1 -C 4 -alkoxy, Ci-Ci-halogenoalkoxy and / or Ci-Ci- alkylthio;
Phenyl or naphthyl, which may be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxy, Ci-C-alkyl, C-Cj-haloalkyl, C! -C4-lcoxy, C? -C4 -halogen Ieoxi, phenoxy, C: -C < -alkyl-r.io, amino, Cj-Cj-alkylamino or Ci-Ci-dialkylamino;
R4 and R- 'together form with the neighboring carbon atom a ring of 3 to 8 members, which may contain an oxygen or sulfur atom and carry one to three of the following radicals: CN-C ^ -alkyl, halogen, Cι-C 4 -halogenalkyl, C?-C 4 -alkoxy, d-C'-haloalkoxy and / or C ?C 4 -alkylthio;
R- 'hydrogen, Ci- -alkyl, Crj-Cr-alkenyl, Cv.-Cf, -alkynyl, C3-C;: - cycloalkyl ?, C: -C4-haloalkyl, C? -C4-alkoxyalkyl, Ci -C ^ -alkylthioalkyl, phenyl, or R5 is linked with R'3, a as indicated above, forming a ring of 3 to 8 members;
R'.sub.5 -C.-C, -alkyl, C -.-C.-ayenyl, C.-Cg-alkynyl or C3-C0-cycloaikyl, the radicals of which may be mono- or polysubstituted by: halogen, nitro , cyano, d ^ -alco i, C -C-alkykennyloxy, C -.- C ^ -alkynyloxy, C? -C < -alkylthio, C? -C,? -haloalkoxy, C? -C? -alkylcarbonyl, C? -C4-alkoxycarbonyl, C: -C4-alkylamino, di-Ci-Cj-alkylamino, phenyl, mono or polysustitutes, eg mono to trisubstituted by halogen, nitro, cyano, C -, - C4-alkyl, Ci-C ^ -halogenoalkyl, Ci-Cj-alkoxy, C? -4-haloalkoxy or phenyl substituted by C - Ci-alkylthio, or phenoxy;
phenyl or naphthyl, which may be substituted each time by one or more of the following radicals: halogen, nitro, cyano, hydroxy, amino, C 1 -C 4 -alkyl, C: -C 4 -halogenalkyl, C-. -C¿-alkoxy, C; -C, α-haloalkoxy, phenoxy, Cj-C-aL-alkylthio, C; -C¿-alkylamino or Ci-Q-dialkylamino;
a heteroaromatic of five or six members, containing one to three nitrogen atoms and / or one sulfur or oxygen atom, which may carry one to four halogen atoms and / or one up to doe of the following radicals:
C-C-alkyl, C? -C,; -halogenoalkyl, C-, -C4-alkoxy, dC.-halogenoalkoxy, Ci-Ci-alkylthio, phenyl, phenoxy or pheylcarbonyl, whose phenyl radicals can carry their part one to five halogen atoms and / or one to three of the following radicals: C? -C4-alkyl, C? -C4-alkoxy, C? -c < -halogenoalkoxy and / or C? -C4 -alkyi;
And sulfur or oxygen or a simple bond;
Z dufre or oxygen.
For the preparation of the compounds of the invention, starting from the IV epoxies, which are prepared in a known manner, for example in the manner described in J. March, Advanced Organic Chemistry, 2nd ed. , 1983, p. 862 and p. 750, from aldehydes or ketones II or olefins III;
The carboxylic acid derivatives of the general formula VI can be prepared by reacting the epoxides of the general formula IV (for example with R = C00Rlü) with alcohols or thioles of the general formula V, in which R6 and Z have the meaning indicated in claim 1,
R4 6 IV + RÓZH * > R Z C s: CH OH VI
v 'i' R
For this, the compounds of the general formula IV are heated with an excess of the compounds of the formula v, eg 1.2-7, preferably 2-5 mol equivalents, at a temperature of 50-200 C , preferably 80-150 ° C.
The reaction can also take place in the presence of a diluent. For this purpose, all inert solvents can be used against the reagents used.
Examples of the solvents or diluents are: water, aiiphatic, alicyclic and aromatic hydrocarbons, which in each case may be chlorinated, such as, for example, hexane, cyclohexane, petroether, ligroin, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethylenic chloride and tpchlorethylene, ethers, such as, for example, diisopropyl ether, dibutyl ether, propylene oxide, dioxane and tetrahydrofuran, cer. such as, for example, acetone, methyl ethyl ketone, methyl isopropyl ketone and methyl isobutyl ketone, nitriles, co or P-ex. acetonitrile and propionitrile, alcohols, such as, for example, methanol, ethanol, isopropanol, butanol and ethylene glycol, esters, such as, for example, ethyl acetate and amyl acetate, acid amides, e.g. di methylformamide and dimethylacetamide, sulfoxides and suifones, such as, for example, dimethyl sulfoxide and sulfolane and bases, with, for example, pyridine.
The reaction can be carried out preferably in a temperature range of between 0 ° C and the boiling point of the solvent or solvent mixture.
The presence of a reaction catalyst can be advantageous. As catalysts sor. appropriate strong organic and inorganic acids, as well as Lewis acids. Examples are: sulfuric acid, hydrochloric acid, trifluoroacetic acid, boric trifluoride etherate and the titanium (IV) alcoholates.
The computates of the invention in which Y means oxygen and the other solvents have the meaning indicated for the general formula i, they can be prepared, for example, in such a way that the carboxylic acid derivatives of the general formula VI, where the substituents have the indicated meaning, they are reacted with compounds of the general formula vil,
VII
wherein R1S stands for halogen or R1 (1- S-2-, representing R * 6 C? -C4-alkyl) C? ~ c, -halogenoalkyl or phenyl The reaction preferably takes place in one of the diluents mentioned above, adding an appropriate base, namely, a base, which produces the deprotonation of intermediate VI, at a temperature range from room temperature to the boiling point of the solvent.
As the base, an alkali metal or alkaline-iron hydride, such as or, may be used. ex. sodium hydride, potassium hydride or calcium hydroxide, a carbonate, such as, for example, an alkali metal carbonate, eg sodium carbonate or potassium carbonate, an organic metal compound, such as p. ex. but..lite or an alkaline amide, as p. ex. lithium diisopropylamide.
The compounds of the invention, in which Y means sulfur and the other substituents have the meaning indicated for the general formula I, can be prepared, for example, by reacting carboxylic acid derivatives of the general formula VIII, obtained in a known manner from starting from compounds of the general formula VI, and in which the substituents 0
they have the meanings indicated above, with compounds of the general formula IX, in which R-, R3 and x have the meanings indicated for the general formula I.
The reaction is preferably lauded in one of the diluents mentioned above, adding an appropriate base, namely a base which produces the deprotonation of intermediate IX, in a temperature range of between room temperature and the boiling temperature of the product. solvent.
As bases are appropriate in addition to the bases mentioned above, also organic bases, such as tertiary amines, p.sj. triethylamine, pyridine, imidazole or diasabicycloundecene.
The compounds of the formula I can also be prepared, starting from the corresponding carboxylic acids, to form compounds of the formula I, wherein R 1 is hydroxyl, and these are first converted, in a customary manner, into an activated form, such as A halide, an anhydride or imidaso-lide, and reacting this, then, with a corresponding hydrixyl compound H0R1C. This reaction can be carried out in customary solvents, and frequently requires the addition of a base, the abovementioned being suitable as such. These two steps can be simplified, for example by activating the carboxylic acid in the presence of a water separating agent, such as a carbodiimide, on the hydroxyl compound.
In addition, the compounds of the formula I can also be obtained, starting from the corresponding carboxylic acids, ie, compounds of the formula I, wherein R represents a group C0Rt and R1 means OM, where M can be an alkali metal cation or the equivalent of an alkali-iron metal cation. These salts can be reacted with a number of compounds of the formula R-A, meaning A a customary non-halogen dispersible group, such as, for example, chlorine, bromine, iodine or arylsulfonyl or alkylsulfonyl optionally substituted by halogen, alkyl or haloalkyl, such as, for example, toluenesulfo-nyl and methylsulfonyl or another equivalent dissociative group.
Compounds of the formula R.sup.-A with a reactive Y substituent are known or can easily be obtained by applying general professional knowledge. This reaction can be carried out in customary solvents and is carried out, preferably, by adding a base, the bases indicated above being lent.
The radical R in formula i can have a widely variable meaning. For example, R can mean a group Q
C-R1
where R1 has the following meanings:
a) hydrogen;
b) a sucoinimidyloxy group;
c) a five-membered heteroaromatic linked via a nitrogen atom, such as, for example, pyrrolyl, pyrazolyl, imidazoiyl and triazolyl, which can carry one to two halogen atoms, especially fluorine and chlorine and / or one to two of the following radicals:
Ci-C-alkyl, eg methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl], 2-methyl-1-propyl, 1-butyl, 2-butyl;
C 4 -Chaloalkyl, especially C 1 -C 2 -haloalkyl, such as, for example, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, chlorofluoromethyl, trichloromethyl, 1-fluoroethyl, 3-flylmethyl, 2, 2-difluoroethyl, , 2,2-trifluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl;
C 1 -C 4 -haloalkoxy, especially C 1 -C 2 -haloalkoxy, eg difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, i-fluoroethoxy, 2-fluoroethoxy, 2,2-di-toluoroethoxy, 1, 1,2, 2-tetrafluoroethoxy,, 2, -trifluoroethoxy, 2-chloro-l, 1,2-trifluoroethoxy and pentafluoroethoxy, especially trifluoromethoxy;
Ci-Cj-alkoxy with, for example, methoxy, ethoxy, propoxy, 1-methyloxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, especially methoxy, ethoxy, 1- methylethoxy;
C-J-C4"alkyl, methylthio, ethyl, propylthio, 1-methyl ethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, 1,1-dimethylethylthio, especially methylthio and ethylthio;
d) R7
where m is 0 or 1 and R7 and Rs, which may be identical or different, have the following meanings:
hydrogen
C.-C3-alkyl, especially Ci-d-alkyl, as the above-mentioned;
CjC.; - alkenyl, p.-ej ... 2-propenyl, 2-butenyl, 3-butenyl, 1-methy1-2-propenyl, 2-methyl-2-propenyl, 2-pentenenyl, 3-pentenyl, 4-? Entenyl, l-methyl-2-butenyl, 2-methyl-2-butenyl, 3-metii-2-butenyl, 1-methyl-1-butenyl, 2-methyl-3-butenyl , 3-methyl-3-butenyl, 1, l-dimethyl-2-propenyl, 1, 2-dimethyl-2-propenyl »l-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4 -hexenyl, 5-hexenyl, l-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, l-methyl-4- pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenenyl, 4-methyl-4-penteryl, 1,1-dimethyl-2-butenyl, 1,1-dimethy. .3-butenium, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl , 2,2-dimethyl-3-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-ba enue, l-etü-2-butenyl, l-ethyl-3-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, l-ethyl-l-methyl-2-propepyl and l-ethyl-2 -methyl-propenyl, especially 2-propenyl, 2-butenyl, 5-methyl-2-butenyl and 3-methyl-2-pentenyl;
C -, - C (5-alkenyl), eg 2-propinyl, 2-butinyl, 3-butylene, 1-me-L-2-propinyl, 2-pentynyl, 3-pentynyl, 4-? entinyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 1-methyl-2-butynyl, 1, 1-dimethyl-2-pypinyl, 1-ethyl-2-propynyl, 2-Hexynyl, 3-Hexynyl, 4-Hexynyl, 5-Hexynyl, 1-Methyl-2-Pentnyl, 1-Methyl-3-Pentynyl, 1-Methyl-4-Pentyne-1-methyl-3-Pentynyl , 2-methyl-4-peptinyl, 3-methyl-4-pentynyl, 4-methyl-2-pentynyl, 1, ld? Methyl-2-butynyl, 1, l-din? Et? L- 3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-d? Methyl-3-butynyl, l-ethyl-2-butynyl, l-ethyl-3-butynyl, 2-ethyl-3- butynyl and l-ethyl-l-methyl-2-propynyl, preferably 2-propynyl, 2-butynyl, l-methyl-2-propynyl and l-methyl-2-butyl, especially 2-propynyl
Cr.-C? -cycloalkyl, eg cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, whose alkyl, cycloalkyl, alkenyl and alkynyl groups can each carry one to five halogen atoms, especially fluoro or chlorine and / or one to two of the following groups: 25 C -C4-alkyl, C_-C4-alkoxy, C? -C4-alkylthio, C? -C4-halogenoalkoxy, with the abovementioned, C3-C4 -alkenylsxy, CC? -alkenylthio, Cj-C-alkyloxy, Cs-Cj-alkynedis, having the alkenyl and alkynyl components present
The radicals preferably have the meanings indicated above;
C_-C_-alkylcarbonyl, e.g., especially methylcarbonyl, ethylcarbonyl, propylcarbonyl, 1-methyethylcarbonyl, butylcaibonyl, 1-methylpropycarbonyl, 2-methylpropycarbonyl, 1,1-dimethyl-ethylcarbonyl;
C-Cj-alkoxycarbonyl, eg methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, 1-methylethoxycarbonium, butyloxycarbonyl, 1-methylpropylcarbonyl, 2-methylpropyloxycarbonyl, 1,1-dimethylethoxycarbonyl;
C-C,; -alkylcarbonyl, C3-C (-; - alkynylcarbonyl, C?, - C: -alkenyloxycarbonyl and C3-C6-alkynyloxycarbonyl, the alkenyl or alkynyl radicals of which are preferably as defined above;
phenyl, optionally mono- or polysubstituted, eg mono-trisubstituted by halogen, nitro, cyano, C? -C4-alkylo, C? -C4-haloalkyl, C? -C4-alC? xi, C-? C-halogenoalkoxy or C: ~ C? -alkylthio, such as, for example, 2-fluorophenoyl, 3-chlorophenyl, 4-bromophenyl, 2-methylphhenyl, 3-nitr-ofenyl, 4-cyanophenyl, 2-trifluoromethylphenyl, 3-methoxy-phenyl, 4-trifluoroethoxyphenyl, 2-methylthiophenyl, 2,4-di-chlorophenyl, 2-methoxy-3-methylphyl, 2-dimethoxypyl, 2-nitro-5-cyanophenyl, 2,6-difluorophenyl;
di-Ci-Ci-alkylamino, eg, especially dimethylamino, diprop lamino, N-propyl-N-methylamino, N-propyl-N-ethylamino, diisopropylcimino, N-isopropyl-N-methylamino, N-iso - propyl-N-ethylamino, N-isopropyl-N-propylamino;
"and Re mean, in addition, phenyl, which may be substituted by one or more, eg one to three of the following radicals: halogen, nitro, cyano, C1-C4-alkyl, C -! - C4-hal? genoa.lkyl, C- | -C-alkoxy, Ci-Cj-halogenoalkoxy or C-C4-alkylthio, such as especially those mentioned above;
or Rv and R5 together form a chain of C4-C, -alkylene closed in ring form and optionally substituted for example by Ci-C-alkyl, and which may contain a hetero atom selected from the group oxygen, sulfur or nitrogen, eg - (CH2) 4-, - (CH2) s-, - (CH5) e ~, - (CH2) 7-, - (CH2) -0- (CH2); - f -CH2 -S- i Crl-¿) 3-, -. { CH2) 2-0- (CH2) 3-, - H-. { CH2) 3-, -CH2-NH- (CH) 2-, -CH2-CH = CH-CH2-, -CH-CH- (CH ^), -? -, •
e) (O)
O:? -: R '
where k has the values 0, 1 and 2, p the values 1, 2, 3 and 4 and R5 means Cx-Cí-alkyl, Ci-Cc-halogenoalkyl, C¡-Cf; -alkenyl, C3-Cf-alkynyl or optionally substituted phenyl, eg especially the above mentioned.
R 'also means a radical OR10, where R1'1 signifies;
hydrogen, the cation of an alkali metal, eg lithium, sodium, potassium or the cation of an alkaline earth metal, eg calcium, magnesium and barium or an organic ammonium ion
harmless to the environment, eg C1-C4-tertiary alkylammonium or the ammonium ion;
C-jCN-cycloalkyl, eg those mentioned above, and which can carry one to three C? -C4-alkyl groups;
Ci-Cn-alkyl, e.g., especially, methyl, ethyl, propyl, 1-melethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, per.ethyl, -I-butyl, 2-methylbutyl, 3- and ilbuyl, 1, -dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methyl-pentyl, 2-methylpentyl , 3-methylpentyl, 4-methylpentyl,
-dimethylbutyl, 1, -dimethylbutyl, 2,3-dimethyl-1, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3, 3-dimethylbutyl, 1,2-trimethylpropyl, 1,2,4-dimethylbutyl -trimethylpropyl, 1-ethylbutyl, 2-ethylbutyl, I-ethyl-2-methylpropyl, which can carry up to five halogen atoms, especially fluoro and chloro, and / or no of the following radicals:
C -, - C4-alkoxy, C- | -C-alkylthio, cyano, C? -C4-alkylcarbonyl, C ', -C, cycloalkyl, C: -C, i-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, whose aromatic radicals can each carry one to five carbon atoms
Halogen and / or one to three of the following radicals: nitro, cyano, Ci-Ci-alkyl, C-Cj-haloalkyl, C: -C.-alkoxy, C? -C, -haloalkoxy and / or C? C4-alkylthio,, e.g. especially the above mentioned;
a C? -C? -alkyl group, eg those mentioned above, and carrying one to five halogen atoms, especially fluoro / or chlorine and one of the following radicals: a five-membered heteroaromatic, containing one to three nitrogen atoms, or a 5-membered heteroaromatic containing a nitrogen atom and an oxygen or sulfur atom, and which may carry one to four halogen atoms and / or one to two of the following radicals:
nitro, cyano, C: -C, -alkyl, C; -C.? -halogenoalkyl, C? -C, -alkoxy, phenyl, C-Cj-haloalkoxy and / or C? -C4-allylthio. They are mentioned, especially: 1-pyrazole, 3-methyl-1-pyrazolyl, 4-methyl-1-pyrazolyl, 3,5-dimethyl-1-pyrazole, 3-phenyl-1-pyrazolyl , 4-phenyl-1-pyrazyl-lyl, 4-chloro-lp-razolyl, 4-bromo-1-pyrazolyl, 1-imidazolyl, 1-benzimidazolyl, 1,2,4-triazol-1-yl, 3 -me-ti1-1, 2, -triazol-l-yl, 5-methyl-l, 2,4-triazol-l-yl, 1-benztriazolyl, 3-isopropylisoxazol-5-yl, 3-methylisoxazole-zol- 5-yl, oxazol-2-yl ?, thiazole-2-ÜO, imidazol-2-yl, 2-ethylisoxazol-b-yl, 3-phenylisoxazol-5-yl, 3-tert-bu-yl isoxasol-5 ilo;
a C6-C, -alkyl group, which carries in the 2-position one of the following radicals: Ci-Ci-alkoimino, C-C6-alkyloxyimino, C3-C? -haloalkenyloxyimino or benzyloxy-imino;
a C3-Cfi-alkenyl group or whose groups can in turn carry one to five halogen atoms;
R1 * -1 also means a phenyl radical, which can carry one to five halogen atoms and / or one to three of the following radicals: nitro, cyano, Ci-C-alkyl, C? -C,? haloalkyl, C [alpha] -C4-alkoxy, Ci-C [alpha] -haloalkoxy and / or C [beta] -4-alkytiio, for example, especially those mentioned above;
a five-membered heteroaromatic linked via a nitrogen atom, containing up to three nitrogen atoms, and which can carry one up to two halogen atoms and / or one to two of the following radicals: C? -c4-aikyl, C 1 -C 4 -halogen-alkyl, C 4 -C-alkoxy, phenyl, C 4 -C 4 -halogencalcyl, and / or C 1 -C 4, -alkylthio. They are mentioned, especially: 1-pyrazolyl, 3-methyl-1-pyrazolyl, 4-methyl-1-pyrrazolyl, 3, 5-dimethyl-1-pyrazolyl, 3-phenyl-1-pi-razolyl, 4-phen Pyrazolium, 4-chloro-1-pyrazolyl, 4-b-omo-1-pyrazolyl, 1-midazolyl, 1-benzimidazolyl,
1,2,4-triazol-1-yl, 3-methyl-1,2,4-triazol-1-yl, 5-methyl-1, 4-triazol-1-yl, 1-benstriasolyl, 3 , 4-dichloroimi- dazol-1-i] o;
R1 'also means a group where P i and R ^, which may be identical or different, mean:
Ci-CV-alkyl, C3-Cg-alkenyl, Cs-Cs-alkynyl, C2-Cs-cycloalkyl, whose radicals can carry C? -C4-alkoxy, C: -C? -alkylthio and / or a phenyl radical optionally substituted, for example, in particular, as mentioned above;
phenyl, which may be substituted by one or more, eg one to three of the following radicals: halogen, nitro, cyano, C? -C.-alkyl, Ci-Cj-haloalkyl, C? -C4-al -c? xi, C? -C-halogenoalco? io C | -C4-alkytio, whose radicals co respond, especially to those mentioned above;
or R11 and 12 together form a chain of Cj-C? 2-alkylen, which may contain one to three chyl groups and one heteroatom of the group oxygen, sulfur and nitrogen, eg especially those mentioned for R 'and R «.
RJ- means, in addition, a radical
-NH II R 13
OR
where R1- means:
C? -C4-alkyl, -C3-C? -alkenyl, Cj-CV-alkynyl, C'j-C3-cycloalkyl, as especially those mentioned above, whose radicals can carry a C? -C4-alkoxy radical, C? -C'4-al? Iui.ltio and / or phenyl, as those mentioned above;
phenyl, optionally substituted, as especially those mentioned above.
With respect to their biological action, the carboxylic acid derivatives of the general formula I are preferred, in which the substituents have the following meanings:
R ~ the C] -C4-alkyl, C ': - C_-halogenoalkyl, C3. ~ C4-alkoxy, Ci-Cj-halogenoalkoxy, Ci-Cr-alkylthio groups mentioned in detail for R1 and halogen atoms, especially chlorine, methyl, methoxy, ethoxy, difluoromethoxy, trifluoromethate, especially methoxy;
X nitrogen or C 34, where
K is hydrogen or together with R3 forms an alkylene or alkenylene chain with 4 to 5 members, in which each time a methylene group is replaced by oxygen, eg -CH¿-CH-0-, -CH = CH-0-, -CH-CHj-CH2-0-, -CH = CH-CH20-, especially hydrogen and -CH1-CH2-0-;
R- 'means the groups C? -4-alkyl, C? -C4-haloalkyl, Ci-C? -alkyl, C? -C4-haloalkynoalkoxy, C? -C4-alkylthio mentioned for R1 and halogen atoms, especially chloro, methyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, or form with H1 *, as indicated above, a 5- or 6-membered ring; R means, above all, methoxy;
C - C -, -, - alkyl, eg those mentioned in detail for Ri, and which can carry up to five halogen atoms, eg fluoro, chloro, bromo, iodo, especially fluoro and chloro and / or one of the following radicals: alkoxy, alkylthio, cyano, alkycarbonyl, alkoxycarbonyl, phenyl, phenoyl, phenyleptopyl, eg those mentioned generally and especially for R1;
-Cio-alkyl, eg those mentioned above, and which can take up to five halogen atoms, eg those mentioned above, especially fluoro and chloro, and a heteroaromatic optionally substituted with 5 members, e.g. eg one of the above mentioned for R1;
C-~ C ': -cycloalkyl? > , especially C3-C7-cycloalkyl or Ci-Ci-cycloalkenyl, especially C4-C7-cycloalkenyl, wherein in the saturated or unsaturated ring an eti-iene group may be substituted by an oxygen or sulfur atom, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydrofuranyl, tetrahydro-triemyl, tetrahydropyranyl, tetrahydrothiopyranyl, cyclo-propenyl, dihydrofuranyl, dihydrothienyl, dihydropyranyl, dihydrotopyranyl, whose cycloalkyl or cycloalkenyl radicals may be substituted by one to five halogen atoms, eg those mentioned above, especially fluoro or chloro and / or one of the following radicals: C? -C4-alkyl ?, Ci-Ci-alkoxy, C? -C4-alkylthi ?, cyano, C C -C-alkylcarbonyl, Ci-Ce-alkoxycarbonyl, phenyl, phenoxy, phenylcarbonyl, eg those mentioned above and especially;
C; -C7-alkenyl or G > -C,; -alkynyl, eg the encylo- scripts 5 for R "-, and which can carry one to five halogen atoms, eg those mentioned above, especially fluorc and chlorine and / or one of the following radicals :
C] -C4-alkyl, Ci-C4-alkoxy, C-C4-alkylthio, cyano, Q C -? - Ctf-alkylenecarbonyl, Ci-Cg-alkoxycarbonyl, phenylene, phenoxy, phenylcarbonyl, eg the above mentioned generally and specifically;
a five or six membered heteroaryl, eg furyl, thienyl, pyrryl, pyrazolyl, idol, triazolyl, iso azolyl, oxazolyl, isothiazolyl, thiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triaeinyl, example, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl. 3-isoxasolyl, 4-isoxasolyl, 5-issxazo-20 lyl, 3-isoL.-aiazolyl, 4-isothiazolyl, 5-icothiazole, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiao-olyl, 2-ylidazolyl, 4-imidazsyl, 5-imi - dazolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, oxa-2,4-diazolyl, oxa-3 , 4-diazoylyl, thia-, 4-diazolyl, thia-3, 4-diazolium and triazolyl, whose heteroaromatics can carry one to five halogen atoms, eg those mentioned above, especially fluoro and chloro and / or one up to three of the following radicals:
C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 4 -C alkylthio, cyano, nitro, C x -C g alkylcarbonyl, C 3 -C 6 alkoxycarbonyl, phenyl, phenoxy, phenylcarbonyl, eg the above mentioned generally and especially;
R'- further denotes phenyl or naphthyl, which may be substituted by one or more, eg one to three of the following radicals: halogen, nitro, cyano, hydroxy, mercapto, amino, C? -C -alkyl, C? -C4-halogensalkyl,
C | -C4 ~ -alkoxy, C'i-Ci-halogenoalkoxy, C? -C4 -alkyl, C: -C4-alkylamino, di-C? -C4-alkylamino, C? -C4-alkylcarbo-nyl, C? ~ C4-alkoxycarbonyls, especially, eg those mentioned for R7 and Rr ', such as, for example, 3-hydroxyphenyl, 4-dimethylaminophenyl, 2-mercapto-phenyl, 3-methoxycarbsnyl-phenyl, 4-acetylphenyl, 1-naphtyl, 2-naphthyl, 3-bromo-naphthyl, 4-methyl-1-naphthyl, 5-methoxy-1-naphthyl,
6 ~ trifluoromethyl-l-naphthyl, 7-chloro-l-naphyl, 8-hi-droxy-1-naph il ?;
or Rc and R together form with the neighboring carbon atom a ring with 3 to 6 members, which may contain an oxygen or sulfur atom and which is unsubstituted, or which, depending on the size of the ring, carries one to three The following radicals:
Ci-Ci-alkyl, Cr-C4-alkoxy, C 1 -C 4 -haloalkyl ?, C 1 -C 4 -halogenoalkoxy, C 1 -C 4 -alkylthio, p. ex. the above mentioned generally and especially;
Rfi hydrogen, Ci -C ^ -alkyl, C3-C-lkenyl, C-C-alkynyl, C3-Cfi-cy-cloalqui lü, C? -C4-hai Ógehoalquí l? , C: -C'4-alkoxial ~ q? ilo, C.?--C4-aIc?uiltioalsuilo or phenyl, p. ex. especially those mentioned for R;
Rc C -, - Cy-alkyl, Cv-Cf-alkenylc, Cj-Cg-alkynyl or C3-Cfi-cycloalkyl, eg especially those mentioned above, and q? E may in each case be mono or polysustitides by : halogen, nitro, cyano, Cj-C4-alkoxy, C -., - C?; - lkenyloxy, Cj-Cinylalkyloxy; C.-C_-alkylthio, d-Cj-halogenoalco?, C? -C4-alkylcarbonyl, C-C4-alkoxycarbonyl, C'i-C? -alkylamino, di-CC-alkylamino, or phenyl or phenoxy optionally substituted, eg especially those mentioned above;
phenyl or naphthiio, which may be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxy, amir.o, C? -C4-alkyl, Cj-C-haloalkyl, C? -C. : -alkoxy C1-C4-halogenoalkoxy, phenoxy, Cj-Ca-alkylthio, Ci- -alkylamino or C? -C4-dialkylamino, eg, especially those mentioned for Rv and R4;
a heteroaromatic of five or six members, containing one to three nitrogen atoms and / or one sulfur or oxygen atom, and which may carry one to four halogen atoms and / or one to two of the following radicals: C1-C4 -alkyl, CL-C, -halogenoalkyl, Ci-Clycoxy, C 1 -C 4 -haloalkoxy, C. -C 4 -alkylthio, phenyl, phenoxy or phenylcarbonyl, the phenyl radicals of which may contain one to five halogen atoms and / or one to three of the following radicals: C | -C4-alkyl, Cx-C-haloalkyl, C C 4 -alkoxy, Ci-Cj-halogenoalkoxy and C 1 -alkylthio, eg, especially those mentioned * for R 4;
And sulfur, oxygen or a simple bond
Z sulfur or oxygen.
Especially preferred are compounds of formula I, wherein R2 and 3 mean methoxy and X is CH. In addition, compounds of the formula i are preferred, wherein R 2 and R 3 signify methoxy, X signifies CH, Y and Z signify oxygen and R- 'is C 1 -C 4 -alkyl. An especially preferred radical in the case of R.sub.1 is the group R.sub.R "', wherein R.sub.10 denotes hydrogen or C.sub.C.-C.
R 4 K "1 represents, especially Ci-Cj-alkyl, optionally substituted phenyl or a heterocyclic radical containing a heteroatom, for example fucyl or thienyl.
R6 represents, in particular, phenyl, optionally mono- to trisubstituted by halogen, 1-C4 -alkyl, C1-Cj-alkoxy and / or C? -C /? -alkyl -i or.
Examples of preferred compounds are indicated in the following table.
Parß? L US ° SeSÜn in-ión «b stacar, especially, compounds 4.42 and 4.58 (ßjempio 10, table 4).
Table
-
0
The compounds according to the present invention offer a new therapeutic potential for the treatment of hypertonia, pulmonary hypertension, myocardial infarction, angina pectoris, acute renal failure, renal insufficiency, cerebral vasospasm, cerebral ischemia, subarachnoid hemorrhages, migraine, asthma, atherosclerosis, endopoxic shock, organic failure induced by endotoxin, intravascular coagulation, restenosis after angioplasty and renal insufficiency induced by cyclosporine, or hypertonia.
The good action of the compounds can be demonstrated by the following tests:
Linkage studies to the receptor
For the linkage studies, human CHO cells, cloned, ETA receptor expressor and guinea pig membranes from guinea pigs with > 60% ETB, compared to ET receivers
Preparation of the membrane
CHO cells with expression of ETA receptors were multiplied in the medium of F; - with 10% fetal calf serum, 1% glutamine, 100 ü / ml penicillin and 0.2% streptomycin (Gibco BRL , Gaithersburg, MD, USA). After 48 h the cells were washed with PBS and incubated for 5 minutes with 0.05% PBS containing trypsin. Then, it was neutralized with F medium; and the cells were collected by centrifugation at 300 x g. For the lysis of the cells the pellet was washed briefly with lysis buffer. { 5 mM Tris-HCl, pH 7.4 with 10% glycine) and then incubated for 30 min at 4UC at a concentration of 10 v cells / ml of lysis buffer. The membranes were centrifuged for 10 min at 20,000 x g and the pellet was stored in liquid nitrogen.
The cerebellum of the guinea pigs were homogenized in the Potter-Elvejhem homogenizer and generated by differential centrifugation of 10 min at 1,000 x g and repeated centrifugation of the supernatant for 10 min at 20,000 x g.
Linkage assays
For the linkage assay with the ETA and ET & amp; the membranes were suspended in the incubation buffer (50 mM Tris-HCl, pH 7.4, with MnCl, 5 mM, 40 μg / ml bacitracin and 0.2% BSA) in a concentration of 50 μg of protein per Test substance, and incubated at 25 ° C with 25 pM of [125J] -ET? (assay with ETA receptor) or 25 pM of [125J] -RZ (assay with ETp receptor ..}., in the presence or absence of the test substance.The specific binding was determined with 10"7 M ETi. of 30 min the free radioligand and the radioligand were separated by filtration on a GF / B glass fiber filter (whatmap, England) in a Skatron cell collector (S atron, Lier, Norway), and the filters were washed with ice-cold Tris-HCl buffer, pH 7.4 with 0.2% BSA The radioactivity collected on the filters was quantified by means of a pac ard 2200 CA liquid scintillation counter.
The K values were determined by regression analysis, using the L1GAND program.
Table A shows the action of the compounds of formula i determined in the test equipment as K value, [mol / 1].
Table A
Functional in vitro assay system for finding endothelin receptor antagonists (subtype A)
This test system is a functional test for endothelin receptors, which is based on cells. Certain cells exhibit an increase in intracellular calcium concentration when stimulated with endothelin 1 (ET1). This increase can be measured in intact cells, loaded with calcium-sensitive dyes.
1-fibroblasts isolated from rats, in which an endogenous endothelin receptor of subtype A was detected were loaded with the fluorescent dye fura 2-am in the following manner: after trypsinization the cells were resuspended in buffer A (120 mM NaCl, 5 mM KCl, 1.5 mM MgCl, 1 M CaCl, 25 mM HEPES, 10 mM glucose, pH 7.4) to a density of 2 x 10 5 / ml and incubated for 30 minutes. min at 37 ° C in the dark with fura 2-am (2 μM), Pluro-nics F-127 (0.04%) and DMSO (0.2%). Then, the cells were washed twice with buffer A and resuspended at 2 x 10 ml.
The fluorescence signal of 2 x 10 - cells per ml was recorded continuously at 30: 'C with? X / EI? I 380/510. The test substances were added to the cells and after a 3 min incubation time with ET1 the maximum change in fluorescence was determined. Controlling the response of the cells to ET1 without prior addition of a test substance, and this response was set equal to 100%.
Table B shows the action determined in this test in the compounds composed of the formula? as IC50 value [mol / 1].
Table B
Assay of ET antagonists in vivo
Male SD rats of 250-300 g were narcotized with obar-btal A, connected to artificial respiration, vagotomized and de-nalized. The carotid artery and the jugularis vein were probed.
In control animals the intravenous administration of 1 μg / kg of ET1 produced a marked increase in blood pressure, which lasted for a prolonged period.
The test animals were injected (1 ml / kg) intravenously 5 min before the administration of ET1 to the test animals. To determine ET antagonist properties, the increase in blood pressure in the test animals was compared with that of the control animals.
"Sudden death" induced by endothelin in rats
The principle of the assay is based on the inhibition of the sudden cardiac death of the mouse produced by endothelin, which is probably due to a constriction of the coronary arteries, by pretreatment with endothelin receptor antagonists. After intravenous injection of 10 nmol / kg of endo-telin in the volume of 5 ml / kg of body weight, the death of the animals occurs within a few minutes.
The lethal dose of in otelin-1 is examined each time in a small collective of animals. When the test substance is applied intravenously, injection of lethal endothelin-1 into the reference group is generally applied 5 minutes later. In the other types of application, the lethal application is carried out, if necessary, until a few hours later.
The percentage of survival is documented and the active doses that protect 50% of the animals 24 hours or more of sudden cardiac death induced by endothelin (ED 50) are determined.
Functional assay of vessels for endothelin receptor antagonists
In segments of the rabbit aorta, after a pretension of 2 g and a relaxation time of 1 h in Krebs-Her.se conductive solution at 37 C and a pK value of between 7.3 and 7.4, first , a contraction of K +. After washing, a curve of endothelin effect is drawn up to the maximum.
Potential endothelin antagonists are applied in other preparations of the same vessel 15 min before the beginning of the endothelin dose-effect curve. The effects of endothelin are calculated in% of the K + contraction. With efficient endothelin antagonists, a shift to the right of the endothelin dose-effect curve occurs.
The compounds of the invention can be administered in a customary manner orally or parenterally. (subcutaneous, intravenous, intramuscular, intraperitoneally). They can also be applied by means of vapors or sprays through the na-sofaringe cavity.
The dose depends on the age, the state and weight of the patient, as well as the way of application. As a general rule, the daily dose of active substance is increased to between approx. 0.5 and 50 mg / kg of body weight in oral administration, and at between approx. 0.1 and 10 mg / kg of body weight in the parenteral administration.
The new compounds can be used in the usual solid and liquid galenic application forms, eg as primers, film tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. . These are prepared in a customary manner, being able to prepare the active substances with customary galenic auxiliaries, such as tablet excipients, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, humectants, dispersants, solvent emulsifiers, retarders, antioxidants. and / or gasses (see H. Sucker et al .: Pharmazeutische Tech-nologie, Thieme-verlag, Stuttgart, 1991). The application forms thus obtained contain the active substance, usually in an amount of 0.1 to 90% by weight.
Synthesis examples
Synthesis of compounds of the general formula VT
Example 1 Methyl ether of 3- ethoxy-3- (3-methoxyphenyl) -2-hydroxybutyric acid
19.5 g (88 nmol) of 3- (3-methoxyphenyl) -2,3-epo-butyric acid methyl ester are dissolved in 200 ml of absolute methanol and mixed with 0.1 ml of boric trifluoride etherate. Stir 12 hours at room temperature and then distill the solvent. The residue is absorbed in acetic ester, washed with sodium carbonate solution and water, and dried over sodium sulfate. The solvent having been distilled, 21.1 g of a lightly liquid oil remain.
Yield: 94% (diastereomeric mixture 1: 1) Example 2 Methyl ester of 3-benzyloxy-3-phenyl-2-hydroxybutyric acid
9.6 g (50 mmoles) of methyl ester of 3-f ni1-2, 3-epoxybutyric acid are dissolved in 150 ml of benzyl alcohol and mixed with 0.5 ml of concentrated sulfuric acid. The mixture is stirred at 50 ° C. for 6 hours and then allowed to cool to room temperature After neutralization with sodium bicarbonate solution, the excess benzyl alcohol is distilled in a high vacuum and the residue is purified by flash chromatography on silica gel with n- hexane / acetic ester 9: 1. Having distilled the solvent, 6.5 g of a colorless oil remain.
Yield: 43% (diastereose mixture was 3: 2)
The compounds indicated in Table 1 are prepared analogously.
Table 1: Intermediate products of the formula VI with Rl s CH- R4 R6-O C-CH-OH R COOCH3
DO NOT. R * R5 DV * 1.1 P.f. ["C] methyl-1-oxyphenyl methyl 1: 1 1.2 benzyl phenyl methyl 3: 2 oil 1.3 methyl oil: > -fluorophene methyl 1: 1 1.4 methyl 4-i-propylphenyl methyl methyl 2-methylphenyl methyl 2: 1 1 .6 methyl omega 3-methylfenyl methyl-1,7-methyl-methyl-phenyl-methyl 3: 2 1,8-methyl-3-nitrophenyl-methyl-1,9-methyl-4-bromofyl-methyl-methyl-3: 1-methyl. 2-furyl methyl 1, 11 methy], or 3-furyl methyl, 12 meyl 2- methyl 1, methyl, 3-thienyl, methyl, 1,14, methyl, 2-pyridyl, methyl, 1,15, methyl, 3-pyridyl, methyl, 1,16, methyl, 4-pyridyl, methyl. methyl 2-thiazolyl methyl 1.18 methyl-isoxazolyl methyl .19 methyl 4-imidazolyl methyl .20 methyl 2-pyrazolyl methyl .21 methyl 4 4-chlorophenyl methyl 2: 1 .22 benzyl oil 3-methylphenyl methyl 1: 1 oil .2: methyl 4-fluorophenyl methyl 1: 1 oil .24 benzyl 4-bromophenyl methyl 1: 1 oil .25 benzyl 4-chlorophenyl methyl 3: 2 oil .26 benzyl 4-f luorophenyl methyl 1: 1 oil .27 methyl phenyl ethyl ITT oil * ratio diastereór.iera
Synthesis of the compounds of general formula I:
Example 3: 3-benzyloxy-3-eneyl-2- (4,6-dimethoxy-pyrimidin-2-yl) -oxibutyric acid methyl ester
3 g (10 mmol) of 3-benzyloxy-3-phe nyl-2-hydroxybuiric acid methyl ester (see 1.2) are dissolved in 40 ml of dimethylformamide and mixed with 0.3 g (12 mimols) of Sodium hydride The mixture is stirred for one hour and then 2.2 g (10 mol.) Of 4,6-di? R, ethoxy-2-methyl-sulphonylpyrimidine are added, and after stirring for 24 hours at room temperature, it is carefully hydrolyzed with 10 ml of water, a pH value of 5 is adjusted with acetic acid and the solvent is distilled in a high vacuum, the residue is taken up in 100 ml of acetic acid ester, washed with water, dried over sodium sulfate and the solvent is distilled. with 10 ml methyl-t-butyl ether and the precipitate is filtered off by suction, after drying 2,4 g of a white powder remain.
Yield: 55% (diastereose mixture was 1: 1) p.f. : 115-117? C Example 4 3-Benzyl acid? I-3-phenyl-2- (4,? -dimetho? Ipyrimidin-2-yl) oxy-butyric acid
1.4 g (3 mmoles) of 3-benzyloxy-3-eneyl-2-acid. { 4,6-dimethoxy-pyrimidin-2-yl) -oxibutyric acid (Ex 3) are dissolved in 20 ml of methanol and 20 ml of tetrahydrofuran and mixed with 3.7 g of 10% NaOH solution. The mixture is stirred at ßO ° C for 12 hours and 12 hours at room temperature, the solvents are distilled off in vacuo and the residue is taken up in 100 ml of water. Now it is extracted with acetic ester to remove unreacted ester. Then, the aqueous phase is adjusted with dilute hydrochloric acid to pH 1-2 and extracted with acetic ester. After drying the sodium sulphate and distilling off the solvent, the residue is mixed with a little acetone and the precipitate formed is filtered off with suction. After drying, 1.2 g of a white powder remain.
Yield: 83% diastereomeric mixture 3: 2 p.f .: 165 ° C (decomposition)
Example 5 3-Benzyloxy-3-phenyl-2- [(4,6-dimetho-i-pyrimidin-2-yl) thio] -butyric acid methyl ester
11 g (25 mmol) of 3-benzyloxy-3-phenyl-2-hydroxybutyric acid methyl ester (Compound 1.2) are dissolved in 50 ml of dichloroethane, 3 g (30 mmol) of tritylamine are added and under stirring 3.2 g (28 mmol) of methanesulfonic acid chloride are added dropwise. It is stirred for two hours at room temperature, washed with water, dried over magnesium sulfate and concentrated in vacuo. The residue is absorbed in DMF and added at 0 ° C to a suspension of 12.9 g (75 mmol) of 4,6-di-methoxyp? imi in-2-thiol and 8.4 g (loo mmoles) of sodium hydrogencarbonate in 100 ml of DMF. After stirring for two hours at room temperature and another two hours at 60 ° C, pour over 1 1 of ice water and filter the precipitate formed by suction. After drying, 3.2 g of a white powder remain.
Yield: 29% l diastereomeric mixture 1: 1)
In analogy to the examples described above, the compounds listed in Table 2 are prepared.
Table 2
Synthesis of compounds of the general formula VI
Example 6
3-phenoxy-3-phenyl-2-hydroxybutyric acid methyl ester
28.2 g (0.3 mol) of phenol and 19.2 g (0.1 mol) of methyl ester of 3-phenyl-2,3-epoxybutyric acid are heated together for 6 hours at 100 ° C. Having distilled the excess phenol in high vacuum and purified the residue by chromatography on silica gel with hexane / acetic ester mixture, 17.9 g of a slightly yellow oil are obtained.
Performance: 62.5%
7
Methyl ester of 3- (4-bromophen? L) or? I-3-phenyl-2-hydro? I-butyric acid
51.9 g (0.3 mol) of 4-bromophenol and 19.2 g (0.1 mol) of 3-phenyl-2,3-epoxybutyric acid methyl ester are stirred for 8 h at 100 ° C and 12 h room temperature. Having distilled the excessive phenol, the residue is purified by flash chromatography (silica gel, n-hexans-acetic ester 9: 1) 7.2 g of a white solid are obtained.
Yield: 20% p.f .: 133 - 135 ° C In analogy the compounds indicated in the Table were prepared
3:
Table .- Intermediate products of the formula VI with R * = CH3 R * I Rb O C - CH - OH R 'COOCH3
Synthesis of the compounds of the general formula I:
Example 8
Methyl ester of 3-phenoyl-i-3-phenyl-2- (4,6-dimethoxypropyl?) - din-2-yl) oxybutyric acid
4.4 g (15.4 mmol) of the methyl ester of 3-phenoxy-3-phe nyl-2-hydroxybutyl acid. 1.1) are dissolved in 40 ml of ida di-methylformate and mixed with 0.46 g (18.4 mmol) of sodium hydride. The mixture is stirred for one hour and then 3.4 g (15.4 mmoles) of 4,6-dimetho-i-2-rcethylsulphonylpyrin.idine are added. After stirring for 24 hours at room temperature, it is hydrolyzed carefully with 10 ml of water, a pH value of 5 is adjusted with acetic acid and the solvent is distilled under high vacuum, the residue is taken up in 100 ml of acetic ester, it is washed with water, dried over sodium sulfate and the solvent is distilled. The residue is mixed with 10 ml of methyl-1-t-bu il ether and the precipitate is filtered off by suction. After drying Queaan 1.6 g of a white powder.
Yield: 24.5% p.f .: 143 - 145 »C
Example 9
3-Phenoxy-3-phenyl-2- (4,6-dimethoxypyrimidin-2-yl) oxybutyl acid
1.3 g of the 3-phenoxy-3-phenyl-2- (4,6-dimethoxypyrimidin-2-yl) oxybutyric acid methyl ester (Ex. 8) are dissolved in 20 ml of MeOH and 40 ml of tetrahydrofuran. , and mixed with 3.7 g of 10% NaOH solution. The mixture is stirred for 6 hours at 60 ° C and 12 hours at room temperature, the solvent is distilled off under vacuum and the residue is taken up in 10 ml of water. The unreacted ester is extracted with acetic acid. Then, the aqueous phase is adjusted with hydrochloric acid to pH 1-2 and extracted with acetic ester. After drying over magnesium sulfate and distilling off the solvent, 1.0 g of a white powder remain.
Yield: 79.7% p.f. : 50 - 55 ° C
Example 10
Methyl ester of 3-phenoxy-3-femyl-2-f (4,6-dimethoxy-pyrimidin-2-yl) io] butyric acid
7.2 g (25 mmol) of the methyl ester of 3-phenoxy-3-phe nyl-2-hydroxybutyric acid are dissolved in 50 ml of dichloromethane, 3 g of 0 mmol) of triethylamine are added and stirring is added dropwise. 3.2 g (28 mmolee) of methanesulphonic acid chloride. Stir 2 hours at room temperature, wash with water, dry over magnesium sulfate and concentrate in vacuo. The residue is taken up in 100 ml DMF and added dropwise at 0 ° C to a suspension of 12.9 g (75 mmol) of 4,6-di-methoxypyrimidin-2-thiol and 8.4 g (100 mmol) of sodium hydrogencarbonate in 100 ml of DMF. After stirring for 2 hours at room temperature and another two hours at 60 ° C, it is poured into 1 liter of ice water and the precipitate is filtered by suction. After drying, 4.2 g of a white powder remain.
Performance; 38% Analogously to the examples described above, the compounds indicated in Table 4 are prepared. Table 4
Claims (1)
- Claiming Use of carboxylic acid derivatives of the general formula I wherein R means a formyl group, a C02H group or a hydrolysable radical in COOH and the other substituents have the following meanings: R2 halogen, C? -C, -alkyl, C? -C4-haloalkyl, C? -C,? -alkoxy, C? -C4-haloalkoxy or C? -C4-alkylthio; x nitrogen or CR1 /; where R14 means hydrogen or together with R3 forms an alkylene or alkenyl chain with 3 to 4 members, in which a methylene group respectively is replaced by oxygen; R3 halogen, C? -C4 alkyl, C? -C4-haloalkyl, coxy, C? -C4-haloalkoxy, Ci-C? -alkylthio or R3 is linked with RiI, as indicated above, forming a ring of 5 or 6 members; R4 a C? -C? -alkyl group, which can carry one to five halogen atoms and / or one of the following radicals: C? -Ci-alkoxy, C: -C4-alkylthio, cyano, Ci-Cg -alkylcarbonyl, Ci-Ce-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, the phenyl radicals being capable of carrying one to five halogen atoms and / or one to three of the following radicals: Cj-Cí-alquüo, C? C4-alkoxy, C? -C4-halogenoalkoxy and / or C; i-C4-alkylthio; a C? -C? -alkyl group, which carries one to five halogen atoms and one of the following radicals: a five-membered heteroaromatic containing one to three nitrogen atoms and / or a sulfur or oxygen atom, which can carry one to four halogen atoms and / or one to two of the following radicals: C? -C4-aikyl, C? -C4-haloalkyl, Ci-Ci-alkoxy, C? -C4-halogenoalkoxy, C? -C α-alkylthio and / or phenyl; a C3-C? 2-cycloalkyl or Ci-Cjj-cycloalkenyl group, which may contain an oxygen or sulfur atom and carry one to five halogen atoms and / or one of the following radicals: C? ~ C, -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -lichthio, cyano, C ?Ce-alkylcarbonyl, Ci-Cι-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, whose phenyl radicals can carry one to five on the other hand halogen atoms and / or one to three of the following radicals: C? -C4? alkyl, C: -C-haloalkyl, Cj-d-alkoxy, C? -C4-haloalkoxy and / or C? -C4-alkylthi?; a C group: - C6-ahenynyl or C3-C6-alkynyl, which may each carry one to five halogen atoms and / or one of the following radicals: C? -C4-alkyl, C? -C4-alkoxy, C?-C4-alkylthio, cyano, Ci-Cs-alkylcarbonyl, C?-C§-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, whose phenyl radicals can in turn carry one to five halogen atoms and / or one to three of the following radicals: C? -C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C? -C4-haloalkoxy and / or C; -C4-alkylthi ?; a heteroaromatic of five or six members, containing 5 one to three nitrogen atoms and / or one sulfur or oxygen atom, which can carry one to four halogen atoms and / or one to two of the following radicals: Ci-C4 -alkyl, c-, - C4-halogenoalkyl, C? -C4-alkoxy, Cl-C4-halogenoalkoxy, C: -C4-alkylthio, phenyl, pheno? -io-nylcarbonyl, whose phenyl radicals can in turn carry one up to five halogen atoms and / or one to three of the radicals: Ci-Ca-alkyl, C-rC4-haloalkyl, C-c4-alkoxy, Ci-Ci-halogenoalcoy, and / or Ci- Cj-alkylthio; Phenyl or nayl, which may be substituted by one or more of the following radicals: halogen, nitro, cyano, hydroxy, C: -4-alkyl, C? -C4-haloalkyl, C? -C4-alkoxy, C? C 1 -haloalkoxy, phenoxy, C 1 -C 4 -alkylthio, amino, Ci-C 4 -alkylamino or C] .- C 4 -diarykylamino; 20 R < I and R5 together form with the neighboring carbon atom a ring of 3 to S members, which may contain an oxygen or sulfur atom and carry one to three of the following radicals: C < -C-alkyl, halogen, C? -C, i-halogenoalkyl, Ci-C4-aico?, C? -C4-halogenoalco? And / or d-c4-alkenylthio; R5 is hydrogen, Ci-Ca-alkyl, Cs-Cg-alkenyl, C3-C6-alkynyl, C3-Cg-cycloalkyl, C? -C4-alkoxyalkyl, C? -C-alkylarylthioacyl, phenyl, or R5 is attached with 30, as indicated above, forming a ring of 3 to 8 members; R6 Ci-Cβ-alkyl, C3-Ci- alkenyl, Cj-Cß-alkynyl or C3-CG-cycloalkyl, the radicals of which may be mono- or polysubstituted by: halogen, nitro, cyano, C? -C4-alkoxy , C3-C6-alkenyloxy, C3-C6-alkynyl?, C? -C4-alkylthio, C? -C4-halogenoalkoxy, C-C4-alkylcarbonyl, C? -C4-alkoxycarbonyl, C1- C4-alkylamino, di-C? -C4-alkylamino, phenyl, Mono- or polysubstituted, eg mono to trisubstituted by halogen, nitro, cyano, C? -C4-alkyl, Cx-Ci-halogenoalkyl, C? -C4-alkoxy, Ci-C-halogenoalkoxy or phenyl substituted by C? -C4 ~ alkylthio, or phenoxy; phenyl or naphthyl, which may be substituted each time 15 by one or more of the following radicals: halogen, nitro, cyano, hydroxy, amino, C? C4-alkyl, C? -4-halogenoalkyl, d-Ci-alkoxy, d-d-halogenoalkoxy, phenoxy, C? -C4-alkylthio, Ci-Cj-aiquiiamino or C? -C4-dialkylamino; A heteroaromatic of five or six members, containing one to three nitrogen atoms and / or one sulfur or oxygen atom, which can carry one to four halogen atoms and / or one to two of the following radicals. C-alkyl, C-Ci-haloalkyl, C? -C4-alko?, C1-C4-h.alogenoal.coxy, C: -C4-alkylthio, phenyl, phenoxy or phe- 25 nylcarbonyl, whose phenyl radicals can carry for its part one to five halogen atoms and / or one to three of the following radicals: C: -C4-alkyl, Ci-Ci-haloalkyl, C? -C4-alco? i, C? ~ C4-halogenoalkoxy and / or C1-C4-alkylthio; 30 And sulfur or oxygen or a single bond, - Z sulfur or oxygen; for obtaining medicines. Summary of the Invention Use of carboxylic acid derivatives of the general formula i wherein R means a formyl group, a C0H group or a hydrolysable radical in COOH and the other substituents have the following meanings: K? -halogen, C: -C 4 -alkyl, C? -C4-haloalkyl, C: -C 4 -alkoxy, C? -C4-halogen-C xi or C: -C_-alkylthio; x nitrogen or CR 1 ', where R 14 signifies hydrogen or forms together with R:' a chain of alkylene o or alkenyl with 3 to 4 members, in which a methylene group respectively is substituted by oxygen; R3 halogen, dC / -alkyl, C? -C4 -haloger.alkyl, C -.- C ^ -alkoxy, Ci-Ca-haloalkoxy, Ci-c4-alkylthio or R3 is linked with R1, as indicated above, forming a ring of 5 or 6 members; R4 is a C? -C-alkyl group, which can contain up to five halogen atoms and / or one of the following radicals: C? -C4-alkoxy, C? -C4-alkylthio, cyano, C: -C3-alkylcarbo - nilo, C -C? -alkoxycarbonyl, phenyl, phenoxy or phenylsarbonyl, the phenyl radicals can on the one hand carry one to five halogen atoms and / or one to three of the following radicals: C.-Ca-alkyl, C? -C4-haloalkyl , Ci-C-a coxy, and / or C? -C4-alkylthio; a group Cj.-C? -alkyl, which carries one to five halogen atoms and one of the following radicals: a five-membered heteroaromatic containing one to three nitrogen atoms and / or a sulfur or oxygen atom, which can carry one up to four halogen atoms and / or one up to two of the? following radicals: C: -C4 ~ alkyl, C-C4-halogen? alkyl, C? -C4-alkoxy, C? -C4-halogenoalkoxy, C: -Ci-a.-alkylthio and / or phenyl; a c., - C?, -; -? cloalkyl or C3-Ci2-cycloalkenyl group, which may contain an oxygen or sulfur atom and carry one to five halogen atoms and / or one of the following radicals: C1- c4-aikyl, C? -C4-alkoxy, C? -C4-alkylthio, cyano, C: -C3-alkylcarbonyl, Ci-Cg-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, whose phenyl radicals can carry per part one to five halogen atoms and / or one to three of the following radicals: C: -Cj-alkyl, C.-C4-haloalkyl ?, C? -C? -alkoxy, Ci-Ci-haloalkoxy and / or Ci -Cy-alkylthio; a C3-C6-aikenyl or C3-C6-alkynyl group, which can each carry up to five halogen atoms and / or one of the following radicals: C? -C4-alkyl, C? -C4-alkoxy, -Ci-alkylthio, cyano, Ci-Cg-alkylcarbonyl, Ci-Cg-alkoxycarbonyl, phenyl, phenoxy or phenylcarbonyl, whose phenyl radicals can in turn carry one to five halogen atoms and / or one to three of the following radicals: d-Ci-alkyl, Ci-CV-alkoalkyl, C? -C4-alkoxy, C? -C? -haloalkoxy and / or C »-C4-alkylthi ?; a heteroaromatic of five or six members, containing one to three nitrogen atoms and one atom of sulfur or oxygen, which can carry one to four halogen atoms and / or one to two of the following radicals: Ci-C4-alkyl , C? -C4-halogenoalkyl, C? ~ C4-alkoxy, CC? -halogenoalkoxy, C? -C4-alkylo, phenyl, phenoxy or fe¬ Nylcarbonyl, whose phenyl radicals can in turn carry one to five halogen atoms and / or one to three of the following radicals: C? -C4-to uyl, C: -C4-haloalkyl, C? -C4-alkoxy, C? -C4"-halogenoalkoxy and / or C? -C4-alkylthio; phenyl or naphthyl, which may be substituted by one or 15 several of the following radicals: halogen, nitro, cyano, hydroxy, C? -c4-alkyl, C? -C4-haloalkyl, C? -C4-alkoxy, C? -C4-haloalkoxy, phenoxy, C? -C4- alkylthio, amino, C? -C4-alkylamino or C? -C < -dialkylamino; 20 R and RB form together with the neighboring carbon atom a ring of 3 to 8 members, which may contain an oxygen or sulfur atom and carry one to three of the following radicals: C? -C4-alkyl, halogen, C ~ C-halogenalkyl, d-C'-alkoxy, Ci-Ca-halogenoalkoxy and / or C? -C4-alkylthio, -25 R5 hydrogen, C - (- C -alkyl, C3-C3-alkenyl, c3-C6-alkynyl, Cj-Cfl-cycloalkyl, C? -C4-haloalkyl, C? -C4-alkoxyalkyl, C? _ C4 -alkyl alkyl phenyl, or R5 is linked with R '1, a as indicated above, forming a ring of 3 to 8 members; R'-C? -C .-; - alkyl, C:, - C-alkenyl, C3-C6-alkylene or C3-Ca-cycloalkyl, the radicals of which may be mono- or polysubstituted by; halogen, nitro, cyano, C? -C4-alkoxy, c3-C6-alkenyloxy, c3-Ci- alkyloxy ?, C! -C4-alkylthio, Cj-C4-halogenoalco?, C; -C4-alkylcarbonyl , C? -C4-alkoxycarbonyl, C: -C4-alkylamino, di-C? -C4-alkylamino, phenyl, mono- or polysubstituted, eg mono to trisubstituted by halogen, nitro, cyano, C? -C4 -alkyl, C? ~ C4-halogenoalkyl, C? -C4-alkoxy, C? ~ C4-halogen lco or phenyl substituted by C? -c4-alkylthio, or phenoxy; phenyl or naphthyl, which may be substituted each time by one or more of the following radicals: halogen, nitro, cyano, hydroxy, amino, C? -C4-alkyl, C? -C4-halogenoalkyl, C-Ci-alkoxy , C? -C4-halogenoalkoxy, phenoxy, C? -C4-aicytthio, C-Cj-alkylamino or C? -C4-dialkylamino; a heteroaromatic of five or six members, containing one to three nitrogen atoms and / or one atom of sulfur or oxygen, which can carry one to four halogen atoms / or one to two of the following radicals: C | -C4- alkyl, C?-C4-haloalkyl, C?-C4-alkoxy, Ci-C4-haloalkoxy, C?-C4-alkylthio, phenyl, phenoxy or phenylcarbonyl, whose phenyl radicals can in turn carry one to five halogen atoms and / or one to three of the following radicals: C? -C4-alkyl, C? -C4-haloalkyl, C-C-alkoxy, C? -C4-halogenoalkoxy and / or d-C-alkylthio and sulfur or oxygen a simple link; z sulfur or oxygen; for obtaining medicines.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4411225A DE4411225A1 (en) | 1994-03-31 | 1994-03-31 | Use of carboxylic acid derivatives as a drug |
DEP4411225.4 | 1994-03-31 | ||
PCT/EP1995/001099 WO1995026716A1 (en) | 1994-03-31 | 1995-03-23 | Pyrimidine or triazine carboxylic acid derivatives to be used as medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
MX9604448A MX9604448A (en) | 1997-07-31 |
MXPA96004448A true MXPA96004448A (en) | 1997-12-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4769742B2 (en) | Pharmaceutical composition having a carboxylic acid derivative | |
USRE42477E1 (en) | Carboxylic acid derivatives, their preparation and use | |
AU714717B2 (en) | Novel carboxylic acid derivatives, their preparation and use | |
EP0969841A1 (en) | Use of carboxylic acid derivatives for treating cancer | |
MXPA96004448A (en) | Use of carboxylic acid derivatives comomedicamen | |
MXPA98008197A (en) | Derivatives of novel carboxylic acids, its preparation and its | |
MXPA98001698A (en) | New derivatives of carboxilic acid, its obtaining and |